- Open Access
Can chemotherapy alone eliminate the transmission of soil transmitted helminths?
Parasites & Vectorsvolume 7, Article number: 266 (2014)
Amongst the world’s poorest populations, availability of anthelmintic treatments for the control of soil transmitted helminths (STH) by mass or targeted chemotherapy has increased dramatically in recent years. However, the design of community based treatment programmes to achieve the greatest impact on transmission is still open to debate. Questions include: who should be treated, how often should they be treated, how long should treatment be continued for?
Simulation and analysis of a dynamic transmission model and novel data analyses suggest refinements of the World Health Organization guidelines for the community based treatment of STH.
This analysis shows that treatment levels and frequency must be much higher, and the breadth of coverage across age classes broader than is typically the current practice, if transmission is to be interrupted by mass chemotherapy alone.
When planning interventions to reduce transmission, rather than purely to reduce morbidity, current school-based interventions are unlikely to be enough to achieve the desired results.
Amongst the world’s poorest populations, funding for the control of soil transmitted helminths (STH) by mass or targeted chemotherapy has increased steadily in the past 10 years due to generous donations from international aid agencies in the richer countries, philanthropic organisations and pharmaceutical companies. Stimulated by the World Health Organisation’s (WHO) 2020 Roadmap on the control of the Neglected Tropical Diseases (NTDs), the spirit of this expanded effort is captured in the London Declaration in January 2012 and the progress report one year later[2–4]. Many questions remain, however, about how best to deliver community based treatment programmes for STH infections to obtain the greatest impact. These include the following: who should be treated, how often should they be treated, how long should treatment be continued for, can treatment intervals be increased as worm loads fall, and can transmission be eliminated by repeated chemotherapy alone?[5, 6]. To answer these questions, a detailed understanding of the transmission dynamics of the parasites is required.
Current guidelines for population-based treatment for STH infections focus on the treatment of pre-school-aged children (pre-SAC) between the ages of 2 to 4 years of age and school-aged children (SAC) between the ages of 5 to 14 years[7, 8], due to measured health benefits and the low cost and simplicity of child health days and school health programmes used to deliver treatment[9, 10]. The impact of increased funding on coverage in these age groups is illustrated in Figure 1, which shows high coverage amongst pre-school-aged children increasing coverage amongst school-aged children. The design and evaluation of many control programmes is based on measures of the prevalence (fraction infected[11, 12]) and intensity of infection (worm loads or parasite egg concentrations in human faeces as a surrogate of worm load[13, 14]). In this paper, we use a mathematical model to investigate the possibility of local elimination of parasites within a community by regular chemotherapeutic interventions and its dependence on the underlying strength of transmission and effective treatment coverage in the key age-groups of pre-SAC, SAC and adults.
The mathematical model used describes the evolution of the parasite distribution in different host age groups and the impact of periodic chemotherapy on host burdens, incorporating the key epidemiological and biological processes influencing transmission. Building on past research[15, 16], it includes the observed features of sexual reproduction by the dioecious helminths, heterogeneity in exposure to infection by host age, variation in the intensity of transmission in different human communities, aggregated distributions of worm numbers per host and a decline in fecundity as a function of worm burden (density dependence)[16–18]. The dynamics of transmission under repeated rounds of treatment is examined for the three main intestinal nematodes, Ascaris lumbricoides, Trichuris trichuria and hookworms (Necator americanus and Ancylostoma duodenale). The model is described in detail in the Additional file1 available online.
Although a full age distribution is embedded in the model, we employ the key age groupings described above to define intervention coverage levels and illustrate their effect. These are infants (0–1 years of age) who cannot be treated under current licensure of the main anthelmintic drugs in wide use (e.g. albendazole and mebendazole), pre-school aged children (pre-SAC, 2–4 years of age), school aged children (SAC, 5–14 years of age) and adults (15+ years of age). Varying combinations of the fraction treated in each age grouping, treatment frequency and duration of treatment are explored. The fraction in each grouping effectively treated is a product of the fraction given treatment and drug efficacy (defined as the proportion of worms expelled). Within the current model, these two aspects of treatment are inseparable, and coverage of the population is represented as a proportion of worms treated. Drug efficacy is typically in the region of 90% or more for Ascaris and hookworms, but somewhat less for Trichuris[19–22]. It should be noted that the fraction treated is effectively chosen at random from the subpopulation. This model does not address systematic non-compliance.
The life cycles of these parasites involve free living stages that are passed in the faeces of the human host and mature to infective stages in the external habitat (eggs for Ascaris and Trichuris and larvae for hookworms). The infective stages of the parasite in the environment are represented in the model by a common pool of infectious material. The life span of these stages is typically weeks to months under favourable environmental conditions, and they are excreted in very large numbers[23–26]. Although this duration is short by comparison with adult worm life expectancies in the human host, infectious material in the environment acts as a reservoir which is unaffected by chemotherapy and can play a significant role in the dynamics of treatment. Dynamics of a range of parasites within the host population can be represented by the same model, with distinct parameter ranges for different species (See Additional file1: Table S1).
Different age groups are thought to both contribute to, and be exposed to, this infective pool to varying degrees. An indication of this is provided by the changes in the intensity of infection by age; the patterns are typically convex for Ascaris and Trichuris, but continue to rise for hookworms as individuals age[27–29] (Figure 2). The respective roles of age related exposure to infection versus acquired immunity remains uncertain, but rapid re-infection by all three parasites post treatment points to the former as the main driver of age-intensity of infection profiles. On this basis, MCMC methods are employed to fit the model to these age related patterns of infection, to estimate both transmission intensity (measured by the basic reproductive number R0 - the average number of offspring produced by one female worm that survive to reproductive maturity) and age related exposure. We have endeavoured to choose typical or characteristic infection profiles for the parasite species investigated in the hope that our results will be broadly applicable.
In the absence of regular treatment, the model exhibits two types of stable behaviour; either the endemic state in which the age profile of infection intensity matches those illustrated in Figure 2, for the respective parasite, or the parasite-free or elimination state. These two states are separated by a ‘breakpoint’ in transmission (created by sexual reproduction which necessitates finding a mate of the opposite sex) close to which parasite population growth is greatly restricted and below which the population decays to extinction. It is possible for a single round of treatment to reduce parasite burdens in the population to a level from which they cannot recover. However, if a single round of treatment can reduce parasite populations to low levels close to the breakpoint, recovery of the parasites may be insufficient to prevent subsequent rounds from driving the population below the break-point. Hence, for a given frequency of treatment and parameterization of the model, we can define critical distributions of treatment among the host population that will eventually lead to elimination of the parasite from the population. Using the parameter estimates for the key epidemiological and biological processes defined in the Additional file1: Table S2, treatment outcomes are explored for a wide range of effective treatment scenarios for the three major age groupings that can be treated (infants cannot be treated). Three different settings are explored, where transmission intensity is low (R0 = 2), medium (R0 = 3) and high (R0 = 5). These stratifications differ somewhat from WHO definitions of low, medium and high transmission settings for reasons defined in the Additional file1, but related to the fact that prevalence, the WHO favoured outcome statistic, is a poor measure of the intensity of infection due to the highly non-linear relationship between these two epidemiological quantities which are drawn from aggregated distributions (variance much bigger than the mean in value) such that large changes in intensity may result in only small changes in prevalence.
The results are presented in two formats; namely, a three dimensional surface of the effective treatment combinations of pre-SAC, SAC and adults that results in crossing the critical treatment surface to extinguish parasite transmission (values equal to or above the surface lead to long term extinction), and time series of repeated treatment of different proportions of the three treatment age groupings to determine how long treatment must continue to the cessation of transmission. These are presented in Figures 3 and4 respectively for the two formats. The parasite with the greatest R0 value determines the intensity, frequency and duration of treatment required. Graphs are for Ascaris and hookworm only, since Trichuris exhibits very similar patterns to Ascaris in terms of its age-intensity profile, excepting drug efficacy is somewhat lower.
A series of general conclusions emerge from these calculations. Annual treatment of only school aged children will rarely extinguish transmission, except in very low Ascaris and Trichuris transmission settings (R0 = 2 or less). For example, when R0 = 2, SAC need to be treated with an overall effectiveness better than 80% for elimination to be achieved (Figure 3a). That is, the product of the fraction of the SAC population covered with the efficacy of the drug must exceed 80%. Once R0 > 2 some of either adults, pre-SAC or both must be treated as well at high coverage levels (Figure 3b,c,e,f). In most settings where Ascaris and/or Trichuris are prevalent, R0 exceeds 2.5 in value[31, 32]. Treating both SAC and pre-SAC, as sometimes carried out by control programmes, with high coverage (>80%) results in good suppression but the ‘breakpoint’ is not crossed. Treating only SAC works even less well if the dominant parasite is hookworm, since most infection and production of infective stages occurs in the adults (Figures 2 and3). In this case, the coverage of the pre-SAC population has almost no impact on the effect of treatment. A large proportion (>50% of the adults must be treated to interrupt transmission in moderate to high transmission settings (Figure 3d,e,f). In medium and high transmission settings, if either Ascaris or Trichuris are the most prevalent infections, the pre-SAC and SAC individuals appear to contribute most to transmission (based on the MCMC estimates of age related infection rates from age-intensity profiles). In these circumstances pre-SAC and adults must be treated as well as SAC with coverage dependent on the value of R0. For very high values (e.g. R0 = 5, Figure 3c) coverage must be above 80% for all age groupings if treatment is annual.
Current guidelines recommend that treatment is administered every 12 months in low-medium transmission settings and every 6 months in high transmission settings[7, 8]. The model results show that the target coverage level can be reduced if treatment is administered more frequently such as every 6 months. This is shown for Ascaris in Figure 3g, where in low to medium transmission settings the critical treatment threshold can be attained by only treating SAC (at above 70% for R0 = 2 and above 90% for R0 = 3). In high settings, treatment levels that do not trigger crossing the treatment threshold surface will have to be sustained indefinitely to avoid a return to pre-control levels. Increasing treatment frequency (every 4 months) and/or changes in behaviour and sanitation that restrict contamination of the environment with infective stages (and hence lower the value of R0) will be required if elimination of transmission is to occur.
The time span over which elimination can be achieved is very sensitive to the details of the intervention and the transmission settings. Figure 4 shows the response of parasite burden in the four age categories to 80% effective coverage for preSAC and SAC. For low values of R0, and yearly treatment for Ascaris, the threshold can be crossed with 10 years at high (80%) treatment coverage (Figure 4a). For 6-monthly treatment, the time is reduced to approximately 6 years (Figure 4d). Treatment at this frequency also allows elimination at R0 = 3. However, the process takes longer than 20 years. As shown in Figure 3, elimination is generally not possible for medium to high transmission. Figure 4b,c,f shows that a new ‘settled’ worm burden has been reached. In general, relaxation of treatment in overall efficacy or frequency leads to a recovery of worm burden in the population. However, preliminary results suggest that if repeated treatment can bring community worm burden sufficiently close to critical level at which elimination is inevitable, it may be possible to relax the intervention without significant recovery for the parasite. This phenomenon is the object of further work.
The surfaces shown in Figure 3 clearly show that elimination of Ascaris purely through school-based deworming is not possible except where transmission settings are at their lowest. Some additional coverage of pre-school children and/or adults is also required. For hookworm, some coverage of adults is essential. The surfaces indicate what ranges of effective coverage will allow elimination but not how long the process may take. As Figure 4 indicates, the elimination goal may be reached in 5–6 years or over several decades and can be very sensitive to the details of treatment coverage and the dynamics of the parasite in the host population.
The optimal approach to treating age groups other than school-age children depends not only on the epidemiological impact but also the practicality and cost-effectiveness of alternative approaches. Perhaps the longest running community-based helminth control programme that treats across all age groups is the African Programme for Onchocerciasis Control (APOC), which has helped countries create a community-directed treatment (CDT) strategy involving both community-directed drug distributors and extending and strengthening health systems[33–36]. The CDT approach is also employed by lymphatic filariasis (LF) control programmes in Africa which administer albendazole and ivermectin (or diethylcarbamazine, DEC) to entire populations aged 2 years and above in LF endemic areas. In addition to the role of community drug distributors, there is a potential for community health workers to deliver treatment, as recently demonstrated for schistosomiasis control in western Kenya and STH control in Ethiopia. A randomised community evaluation in Kenya is currently underway to evaluate the impact and cost-effectiveness of school- versus community-based delivery of albendazole on the transmission of STH in settings with different levels of transmission and species mix. A qualitative evaluation nested within this study will also investigate the acceptability and feasibility of using alternative delivery platforms.
In many poor rural areas of sub-Saharan Africa and southeast Asia long-term commitments to frequent treatment will be difficult to achieve and, as we demonstrate here, in high transmission settings, treatment alone will not interrupt transmission. In such settings, there is a basic requirement to improve hygienic behaviour and access to improved drinking water and sanitation (WASH). The potential benefits of increased access for reducing the risk of STH has been recently highlighted by a systematic review of the associations between STH and water and sanitation which found that people with access to improved water and sanitation facilities were half as likely to be infected with any STH species, with the strongest associations for access to sanitation and use of soap. Levels of access to improved drinking water and sanitation varies greatly within countries, and understanding the geographical inequality in access can help identify areas where treatment can and cannot break transmission. In areas where access is relatively high, there is a real potential to reduce and/or interrupt transmission; in areas where access to water and sanitation remains low, the priority should be on increasing access. Ongoing work is investigating the influence of access to water and sanitation as well as other contextual and programmatic factors on the feasibility of interrupting transmission and mapping those areas where this might be possible.
Our model provides insight into optimal approach to the control of STH, but our approach is not without its limitations. There remains much uncertainty about the nature of transmission dynamics between individuals. While infectious contact rates can be inferred from the baseline infection profile, little can be said about the nature of the infection process or whether a single environmental reservoir is the best model. We have chosen to use the ‘trickle’ model of the infection process rather than the ‘clumping’ model, primarily due to its convenience within a deterministic model paradigm. Other work has shown that the clumping model can have a significant impact on the model’s response to treatment and its sensitivity to parameter values[42, 43]. To resolve these questions will require longitudinal treatment trials, recording data at multiple time-points from both treated and untreated age-groups over 3–5 years. Such trials are currently in progress in Kenya.
Details of model structure and precise parameter values are only important if the behaviour modelled is sensitive to them. In the current paper, we have not included a formal sensitivity analysis, but numerical investigations indicate that the parameter groupings we have focused on (worm lifespan, R 0 and proportion and frequency of effective treatment) are those to which the model is most sensitive. The aggregation of the worms among hosts (k), timescale of infectious material in the environment (μ 2 ) and population demography do not have a strong effect on the results. We investigate assumptions around the deposition of eggs and acquisition of infection in different ages in a follow-up publication.
The current model also does not take into account systematic non-compliance with repeated treatments, which may create a reservoir of transmission that is difficult to reach. It is probable that certain groups are more likely to systematically reject treatment and extra effort is required to target these groups. This phenomenon is the subject of ongoing work.
Global STH control efforts are currently focused on scaling up treatment coverage in school-aged children to 75%, a goal which is justified on the health and education benefits of treating this age group and which is achievable given current drug donation programmes and increased funding. The achievement of this coverage goal should remain the priority of national governments and the international community. However, there is an additional potential to interrupt transmission by expanding treatment to additional age groups and increasing treatment frequency in some settings. Work is underway to validate our models with available data and to evaluate the impact of different treatment strategies in a graded series of randomised evaluations in contrasting transmission settings.
This modelling analysis has shown how the possibility of breaking the parasite transmission cycle depends on the age groups treated, the coverage and efficacy of treatment and the species in question. Our results strongly indicate that when planning to reduce or eliminate transmission, rather than simply reduce morbidity, treatment of school-age children will be insufficient; some treatment of pre-school-age children or adults is necessary, depending on the transmission setting and worm species.
Preventive chemotherapy database, soil-transmitted helminthiases.http://www.who.int/neglected_diseases/preventive_chemotherapy/sth/en/index.html,
London declaration on neglected tropical diseases. 2012,http://unitingtocombatntds.org/resource/london-declaration,
WHO: Accelerating work to overcome the global impact of neglected tropical diseases - A roadmap for implementation. 2012, Geneva: World Health Organization
Uniting to Combat NTDs: From promises to progress: The first anniversary report on the London Declaration on NTDs. 2013,http://unitingtocombatntds.org/resource/promises-progress-first-report-london-declaration-ntds,
Anderson R, Hollingsworth TD, Truscott J, Brooker S: Optimisation of mass chemotherapy to control soil-transmitted helminth infection. Lancet. 2012, 379 (9813): 289-90.
Anderson RM, Truscott JE, Pullan RL, Brooker SJ, Hollingsworth TD: How effective is school-based deworming for the community-wide control of soil-transmitted helminths?. PLoS Negl Trop Dis. 2013, 7 (2): e2027
WHO: Preventive Chemotheraphy in Human Helminthiasis. 2006, Geneva, Switzerland: World Health Organization
WHO: Helminth control in school-age children. 2011, Geneva, Switzerland: World Health Organization, 2
Brooker S, Kabatereine NB, Fleming F, Devlin N: Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up. Health Policy Plan. 2008, 23 (1): 24-35.
Leslie J, Garba A, Oliva EB, Barkire A, Tinni AA, Djibo A, Mounkaila I, Fenwick A: Schistosomiasis and soil-transmitted helminth control in Niger: cost effectiveness of school based and community distributed mass drug administration [corrected]. PLoS Negl Trop Dis. 2011, 5 (10): e1326
Pullan RL, Smith JL, Jasrasaria R, Brooker SJ: Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit Vectors. 2014, 7: 37
Pullan RL, Brooker SJ: The global limits and population at risk of soil-transmitted helminth infections in 2010. Parasit Vectors. 2012, 5: 81
Mwandawiro CS, Nikolay B, Kihara JH, Ozier O, Mukoko DA, Mwanje MT, Hakobyan A, Pullan RL, Brooker SJ, Njenga SM: Monitoring and evaluating the impact of national school-based deworming in Kenya: study design and baseline results. Parasit Vectors. 2013, 6: 198
Nasr NA, Al-Mekhlafi HM, Ahmed A, Roslan MA, Bulgiba A: Towards an effective control programme of soil-transmitted helminth infections among Orang Asli in rural Malaysia. part 1: prevalence and associated key factors. Parasit Vectors. 2013, 6: 27
Holland CV, Asaolu SO, Crompton DWP, Stoddart RC, Macdonald R, Torimiro SE: The epidemiology of Ascaris lumbricoides and other soil-transmitted helminths in primary school children from Ile-Ife, Nigeria. Parasitology. 1989, 99 (Pt 2): 275-85.
Anderson RM, May RM: Infectious Diseases of Humans: Dynamics and Control. 1991, Oxford, UK: Oxford University Press
Anderson RM, May RM: Helminth infections of humans - mathematical models, population dynamics, and control. Adv Parasitol. 1985, 24: 1-101.
Walker M, Hall A, Anderson RM, Basanez MG: Density-dependent effects on the weight of female Ascaris lumbricoides infections of humans and its impact on patterns of egg production. Parasit Vectors. 2009, 2 (1): 11
Michiels M, Hendriks R, Heykants J, van den Bossche H: The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther. 1982, 256 (2): 180-91.
Marriner SE, Morris DL, Dickson B, Bogan JA: Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol. 1986, 30 (6): 705-8.
Levecke B, Mekonnen Z, Albonico M, Vercruysse J: The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura. Trans R Soc Trop Med Hyg. 2012, 106 (2): 128-30.
Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM, Engels D, Guillard B, Nguyen TV, Kang G, Kotze AC, McCarthy JS, Mekonnen Z, Montresor A, Periago MV, Sumo L, Tchueté LAT, Thach DTC, Zeynudin A, Levecke B: Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis. 2011, 5 (3): e948
Yadav AK: Development and survival of Ascaris lumbricoides eggs under the high-rainfall and humid conditions prevailing in Meghalaya, India. Proc Zool Soc Calcutta. 2003, 56 (2): 109-12.
Larsen MN, Roepstorff A: Seasonal variation in development and survival of Ascaris suum and Trichuris suis eggs on pastures. Parasitology. 1999, 119 (Pt 2): 209-20.
Udonsi JK: Experimental and field studies on the viability of eggs, and the infectivity of third-stage larvae of the human hookworm Necator americanus recovered from the creek waters of the Niger Delta, Nigeria, and their epidemiological significance. Parasitology. 1988, 96 (Pt 1): 111-7.
Croll NA, Matthews BE: Activity, ageing and penetration of hookworm larvae. Parasitology. 1973, 66 (2): 279-89.
Thein H, Than S, Htay Htay A, Myint L, Thein Maung M: Epidemiology and transmission dynamics of Ascaris lumbricoides in Okpo village, rural Burma. Trans R Soc Trop Med Hyg. 1984, 78 (4): 497-504.
Bundy DAP, Cooper ES, Thompson DE, Didier JM, Simmons I: Epidemiology and population dynamics of Ascaris lumbricoides and Trichuris trichiura infection in the same community. Trans R Soc Trop Med Hyg. 1987, 81 (6): 987-93.
Pullan RL, Kabatereine NB, Quinnell RJ, Brooker S: Spatial and genetic epidemiology of hookworm in a rural community in Uganda. PLoS Negl Trop Dis. 2010, 4 (6): e713
Gilks WR, Richarson S, Spiegelhalter D: Markov Chain Monte Carlo in Practice. 1995, London: Chapman and Hall
Croll NA, Anderson RM, Gyorkos TW, Ghadirian E: The population biology and control of Ascaris lumbricoides in a rural community in Iran. Trans R Soc Trop Med Hyg. 1982, 76 (2): 187-97.
Hlaing T, Saw T, Lwin M: Reinfection of people with Ascaris lumbricoides following single, 6-month and 12-month interval mass chemotherapy in Okpo village, rural Burma. Trans R Soc Trop Med Hyg. 1987, 81 (1): 140-6.
Amazingo U: The African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2008, 102 (Suppl 1): 19-22.
Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, Goita SF, Konate L, Mounkoro K, Seck AF, Toe L, Toure S, Remme JH: Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012, 6 (9): e1825
Meredith SE, Cross C, Amazigo UV: Empowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria, and Uganda. Health Res Policy Syst. 2012, 10: 16
Mohammed KA, Deb RM, Stanton MC, Molyneux DH: Soil transmitted helminths and scabies in Zanzibar. Tanzania following mass drug administration for lymphatic filariasis-a rapid assessment methodology to assess impact. Parasit Vectors. 2012, 5: 299
Global programme to eliminate Lymphatic Filariasis: Progress report 2000–2009 and strategic plan 2010–2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. 2010, Geneva: World Health Organization
Omedo MO, Matey EJ, Awiti A, Ogutu M, Allaii J, Karanja DSM, Montgomery SP, Secor WE, Mwinzi PNM: Community health workers’ experiences and perspectives on mass drug administration for Schistosomiasis control in Western Kenya: the SCORE project. Am J Trop Med Hyg. 2012, 87 (6): 1065-72.
King JD, Endeshaw T, Escher E, Alemtaye G, Melaku S, Gelaye W, Worku A, Adugna M, Melak B, Teferi T, Zerihun M, Gesese D, Tadesse Z, Mosher AW, Odermatt P, Utzinger J, Marti H, Ngondi J, Hopkins DR, Emerson PM: Intestinal parasite prevalence in an area of Ethiopia after implementing the SAFE strategy, enhanced outreach services, and health extension program. PLoS Negl Trop Dis. 2013, 7 (6): e2223
Strunz EC, Addiss DG, Stocks ME, Ogden S, Utzinger J, Freeman MC: Water, sanitation, hygiene, and soil-transmitted helminth infection: a systematic review and meta-analysis. PLoS Med. 2014, 11 (3): e1001620
Pullan RL, Freeman MC, Gething PW, Brooker SJ: Geographical inequalities in use of improved drinking water supply and sanitation across sub-Saharan Africa: mapping and spatial analysis of household survey data. PLoS Med. 2014, 11: e1001626
Walker M, Hall A, Basáñez MG: Trickle or clumped infection process? A stochastic model for the infection process of the parasitic roundworm of humans, Ascaris lumbricoides. Int J Parasitol. 2010, 40 (12): 1381-8.
Anderson RM, Medley GF: Community control of helminth infections of man by mass and selective chemotherapy. Parasitology. 1985, 90: 629-60.
Anderson R, Truscott J, Hollingsworth TD: The coverage and frequency of mass drug administration required to eliminate persistent transmission of soil-transmitted helminths. Phil Trans R Soc Lond B Biol Sci. 2014, 369 (1645): 20130435
Krentel A, Fischer PU, Weil GJ: A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis. 2013, 7 (11): e2447
This work is supported by the Bill & Melinda Gates Foundation (#OPP1033751) and the Partnership for Child Development. SJB is supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Science (098045). TDH is a member of the Centre for Applied Health Research & Delivery (http://www.lstmliverpool.ac.uk/research/cross-cutting-themes/cahrd/) which is supported by a Wellcome Trust Institutional Strategic Support Award (no. 097830/Z/11/A-C) to LSTM.
Roy M. Anderson is non-executive member of the board of GlaxoSmithKline (GSK). GlaxoSmithKline played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
RMA, TDH & JT contributed equally to the design of the study, equation formulation, analysis and writing of the paper. SB contributed to the design of the study and writing of the paper. All authors read and approved the final version of the manuscript.
James E Truscott, T Déirdre Hollingsworth contributed equally to this work.